SlideShare uma empresa Scribd logo
1 de 6
Baixar para ler offline
Endorsed By 
A N N U A L 30TH 
New Treatments 
in Chronic 
Liver Disease 
FRIDAY, MARCH 20 – SUNDAY, MARCH 22, 2015 
MARCH 3 1 - A P R I L 1 , 2 0 1 2 
Pre-Conference: Friday, March 20, 2015 
Main Conference: Saturday, March 21 – Sunday, March 22, 2015 
Estancia La Jolla • La Jolla, California
Course Introduction Faculty 
course o verv i ew 
This CME conference will review new medications and therapies that are now 
available, or will soon be available, and discuss their comparative values. The 
results of trials using new drugs to treat chronic viral hepatitis B and C, non-alcoholic 
course d i r e ctor 
Paul Pockros, MD, FACG 
Director, Liver Disease Center 
Scripps Clinic 
Director of Clinical Research 
Scripps Translational Science Institute 
La Jolla, California 
scripps f aculty 
Catherine Frenette, MD 
Medical Director of Liver Transplantation 
Director of Center of Excellence for HCC 
Scripps Center for Cell and Organ Transplantation 
Scripps Clinic 
La Jolla, California 
Jill Lane, MD 
Division of Gastroenterology/Hepatology 
Scripps Clinic 
La Jolla, California 
guest f aculty 
Ira Jacobson, MD, FACG 
Chief 
Division of Gastroenterology and Hepatology 
Vincent Astor Distinguished Professor of Medicine 
The Joan Sanford I. Weill 
Medical College of Cornell University 
Attending Physician 
New York – Presbyterian Hospital, Cornell Campus 
New York, New York 
Keith Lindor, MD, FACG 
Executive Vice Provost and Dean 
College of Health Solutions 
Arizona State University 
Phoenix, Arizona 
Rohit Loomba, MD, MHSc 
Associate Professor of Clinical Medicine 
Director, NAFLD Translational Research Unit 
UCSD School of Medicine 
La Jolla, CA 
Lisa Richards, FNP-BC 
Certified Family Nurse Practitioner 
University of California San Diego 
Medical Center 
San Diego, California 
Bruce Allen Runyon, MD 
Clinical Professor of Medicine 
Director of Hepatology 
UCLA Medical Center 
Santa Monica, California 
Norman Sussman, MD 
Associate Professor, Liver Center 
Baylor College of Medicine 
Houston, Texas 
Tram T. Tran, MD, FACG 
Medical Director 
Liver Transplant and Hepatology 
Associate Professor of Medicine 
Cedars Sinai Medical Center 
Los Angles, California 
Faculty Disclosure 
In accordance with the ACCME Standards for Commercial Support, course 
directors, planning committees, faculty and all others in control of the edu-cational 
content of the CME activity must disclose all relevant financial 
relationships with any commercial interest that they or their spouse/partner 
may have had within the past 12 months. If an individual refuses to disclose 
relevant financial relationships, they will be disqualified from being a part 
of the planning and implementation of this CME activity. Employees of a 
commercial interest with business lines or products relating to the content 
of the CME activity will not participate in the planning or any accredited 
portion of the conference. Disclosure will be made to all participants at 
the conference location, prior to the educational activity commencement. 
fatty liver diseases, primary biliary cirrhosis, primary sclerosing chol-angitis, 
hepatocellular carcinoma and complications of end-stage liver disease 
will be reviewed in detail. New Treatments in Chronic Liver Disease is a com-prehensive 
yet concise program for updating physicians on these and other 
commonly encountered problems in the treatment of liver diseases. 
There was a fundamental change in the treatment of chronic hepatitis C in 
late 2014 with the addition of multiple new direct-acting antiviral (DAAs) 
drugs to current standard of care for all genotypes. There will be two separate 
lectures devoted to this topic this year. The first will be on currently available 
all-oral therapies that were approved in late 2014. The second will be on fu-ture 
therapies that will shorten duration and lower cost of a cure. As well, the 
pre-conference will extensively detail currently available treatment regimens 
with the goal of introducing the topic to new treaters. 
We anticipate that there will be a number of new demands placed on treat-ment 
providers, including screening, access to treatment, costs of therapy and 
the continuation of complex algorithms for interferon-based regimens. Look-ing 
beyond 2015, we see numerous combinations of DAA’s in development 
including protease inhibitors, nucleoside polymerase inhibitors, non-nucleo-side 
polymerase inhibitors and N55A inhibitors. Most of these agents are in 
phase 3 development and a number have completed studies and are awaiting 
FDA review. In hepatitis B, the treatments have not changed but there is more 
mature data available on long-term HBsAg loss and clinical outcomes. The ad-dition 
of immune-mediated therapies for HBV with the goal of curing the dis-ease 
has been included in this year’s program. New therapies for NAFLD and 
NASH are in development and important new data showing positive results in 
NASH will be presented at this meeting. The explosive growth of NASH in the 
US has created a significant need for effective drug therapy. The diagnosis and 
treatment of hepatocellular carcinoma will be updated as this disease is one 
of the few cancers with a growing incidence in the US. New oral therapy is 
moving this field forward. There will be an update on management of hepatic 
encephalopathy, hyponatremia and the management of complications in the 
transplant candidate. 
educ ational o b j e c t i ves 
After participating in this course, attendees should be able to: 
• Understand the details of the AASLD guidelines for treatment of HCV 
using DAA’s in IFN-free regimens. 
• Review our current knowledge of NAFLD and non-alcoholic steato-hepatitis 
and explore the use of new agents and approaches to treatment 
of the conditions. 
• Integrate the algorithm for a therapeutic approach to treatment of HBV 
using anti-virals. 
• Discuss therapies for HCV including NS5A, protease and polymerase inhibitors. 
• Update the skills and management required for transplant hepatology. 
• Apply current options of therapy for hepatocellular carcinoma to 
determine the best approach for your patients. 
• Discuss future treatment paradigms for HCV direct-acting antiviral drug. 
• Describe the diagnosis and treatment of PBC and PSC. 
• Integrate treatment options discussed for patients with ESLD due to 
alcohol who have complicating factors such as HCV, NASH or inherited 
genetic disorder. 
• Discuss the issues complicating drug treatment in decompensated 
cirrhosis, hepatic encephalopathy and hyponatremia. 
• Review the management of complications beta-blocker therapy in ESLD.
Program 
pre-conference o verv i ew 
We will review the virology, genotypes, modes of infection of HCV and characteristics of the clinical illness caused by acute 
and chronic infections. Tests for HCV, including PCR assays and genotyping, interpretations and indications for liver biop-sies 
and complications of cirrhosis will all be discussed. We will show how to initiate and monitor patients during treat-ment 
with simeprevir and sofosbuvir, manage side effects of therapy and deal with various patient populations including 
African Americans, HIV-coinfected and ESLD patients. Lastly, new drugs in development including protease inhibitors, 
other nucleoside and non-nucleoside polymerase inhibitors, NS5A inhibitors, and other novel agents will be discussed. 
pre-conference 
Friday, March 20, 2015 
12:30 p.m. Registration 
1 p.m. Welcome & Introduction 
Paul Pockros, MD, FACG 
1:10 p.m. Update on HCV Diagnostics 
Paul Pockros, MD, FACG 
1:40 p.m. Update on Current therapy with IFN-free 
all-oral regimens 
Paul Pockros, MD, FACG 
main conference 
Saturday, March 21, 2015 
7:30 a.m. Registration, Breakfast & View Exhibits 
8 a.m. Welcome & Introduction 
30 years of the Scripps Liver Conference 
Paul Pockros, MD, FACG 
MODERATOR 
Paul Pockros, MD, FACG 
8:15 a.m. Beta-Blockers and ESLD Mortality 
Bruce Runyon, MD 
9 a.m. New Treatments in 
Development for NASH 
Rohit Loomba, MD, MHSc 
9:45 a.m. Break & View Exhibits 
10:15 a.m. Chronic Hepatitis B: Directions Towards 
A Cure? 
Tram Tran, MD 
11 a.m. Debate 
NASH: Treat Everyone with OCA 
When It’s Approved 
Rohit Loomba, MD, MHSc 
NASH: Wait For More Evidence Before 
Treating with OCA 
Bruce Runyon, MD 
11:15 a.m. Panel Discussion: Morning Speakers 
11:45 a.m. Lunch 
MODERATOR 
Catherine Frenette, MD 
W.S. Haubrich Honorary Lecturer 
1 p.m. All-Oral Therapies for HCV 
Ira Jacobson, MD, FACG 
1:45 p.m. HCV: What’s Left for Future Treatments? 
Paul Pockros, MD, FACG 
2:30 p.m. Break & View Exhibits 
3 p.m. Debate #1: 
Treat HBeAg-negative HBV Forever 
Tram Tran, MD 
Stop Therapy in HBeAg-negative HBV 
Patients after Two Years 
Paul Pockros, MD, FACG 
2:40 p.m. Break & View Exhibits 
3 p.m. Pre and Post Liver Transplant 
Catherine Frenette, MD 
3:30 p.m. Case Presentation, Discussion and Q&A 
• Side-Effects Management 
• Selection of Treatment 
• Cirrhosis: Who to Treat 
• Special Populations 
Lisa Richards, FNP-BC 
5 p.m. Adjourn 
Saturday (continued) 
3:15 p.m. Debate #2: 
HCV: Treat For Cure at Any Cost 
Ira Jacobson, MD, FACG 
HCV: Treat For Cost-Effective Cure and 
Salvage Those Who Fail 
Paul Pockros, MD, FACG 
3:30 p.m. Panel Discussion: Afternoon Speakers 
4:30 p.m. Adjourn 
Sunday, March 22, 2015 
7:30 a.m. Breakfast & View Exhibits 
MODERATOR 
Jill Lane, MD 
8 a.m. Emerging Therapies for PBC and PSC 
Keith Lindor,MD, FACG 
8:45 a.m. NAFLD: What To Do For The IBS of 
The Hepatologist? 
Norman Sussman, MD 
9:30 a.m. How to Have a Successful Outcome 
with HCC 
Catherine Frenette, MD 
10:15 a.m. Break & View Exhibits 
10:45 a.m. Debate 
Transplant Outcomes Depend on 
What Region You’re In 
Norman Sussman, MD 
Transplant Outcomes Depend on 
Your ICU Care 
Catherine Frenette, MD 
11 a.m. Panel Discussion 
11:45 a.m. Adjournment
accreditation 
Scripps Health is accredited by the 
Accreditation Council for Continuing 
Medical Education (ACCME) to pro-vide 
continuing medical education for 
physicians. 
Scripps Health designates this live activ-ity 
for a maximum of 13.5 AMA PRA 
Category 1 Credit(s)™. Physicians 
should only claim credit commensurate 
with the extent of their participation in 
the activity. 
Credit Breakdown: 
Pre-Conference (Fri): 3.5 
Main Conference (Sat-Sun): 10 
Nurses: For the purpose of recertifica-tion, 
the American Nurses Credential-ing 
Center accepts AMA PRA Category 
1 Credits™ issued by organizations 
accredited by the ACCME. For the 
purpose of re-licensure, the California 
Board of Registered Nursing accepts 
AMA PRA Category 1 Credits™. Most 
states’ Board of Registered Nursing ac-cept 
AMA PRA Category 1 Credit(s)™ 
as meeting continuing education re-quirements 
for license renewal. Nurses 
should check with their state board re-garding 
use of CME credit. 
Nurse Practitioners: This program will 
be submitted to the American Associa-tion 
of Nurse Practitioners for continu-ing 
education credit. 
Physicians Assistants: The American 
Academy of Physician Assistants accepts 
Category 1 credit from AMA Category 
1 CME organizations accredited by 
ACCME. 
educational gr ants 
This course is supported, in part, by 
educational grants from industry, in 
accordance with ACCME accreditation 
Standards for Commercial Support. At 
the time of printing, a complete list-ing 
of commercial supporters was not 
available. Appropriate acknowledge-ment 
will be given to all supporters at 
the time of the educational activity. 
About William S. Haubrich, MD 
Dr. Haubrich graduated from Franklin & Marshall College in Lacaster, Penn-sylvania 
in 1943 and from the medical school of Case-Western Reserve 
University in Cleveland, Ohio in 1947. His postgraduate training in pathology 
and internal medicine was at Cleveland City Hospital (now MetroHealth). 
His mentor in gastroenterology was Dr. Henry L. Bockus at the Graduate 
Hospital of the University of Pennsylvania in Philadelphia. During the Korean 
War he served as gastroenterologist to the Madigan Army Hospital at 
Fort Lewis, Washington. From 1955 to 1970 he was on the gastroenter-ology 
staff at the Henry Ford Hospital in Detroit. In 1970 he was appoint-ed 
Clinical Member at the Scripps Clinic and Research Foundation where 
he headed the division of gastroenterology from 1972 to 1984. He served as 
Clinical Professor of Medicine at the University of California, San Diego since 
1971. His scholarly contributions include more than 200 journal articles and 
textbook chapters. He was consultant in life sciences to the editors of the 3rd 
and 4th editions of the American Heritage Dictionary of the English Language. 
In 1960 he was awarded the Vincent Lyon Prize by the American Gastroen-terology 
Association and in 1985 received the Rudolf Schindler Award of the 
American Society of Gastrointestinal Endoscopy. He was named a Master of 
the American College of Physicians. Dr. Haubrich passed away peacefully at his 
home in La Jolla in October 2012. 
Conference Location 
Estancia La Jolla Hotel 
9700 N. Torrey Pines Road, La Jolla, California 92037 
855-318-7602 estancialajolla.com 
Please make your own sleeping room reservation, no later than March 3, 2015. 
Mention you are with the Scripps Liver Disease Conference to receive the 
reduced rate of $199 per night, plus the $12 hospitality service fee (dis-counted 
from $17), which includes: Welcome beverage at check-in, guest 
room bottled water daily, wireless internet access in guest room and common 
area, daily newspaper, in room coffee & morning coffee service in Trinitas 
Cellars Wine Bar, local & 800 call access and access to Fitness Center, Internet 
Office and Pool area. 
Download the Scripps CME App 
All conference information including a detailed agenda, faculty listing, faculty 
disclosures, industry support, attendee list, and course materials can be found on 
the free Scripps CME conference app for iPhone, iPad, Android, and BlackBerry. To 
download the app on your smart phone or other device visit the appropriate app 
store and search ScrippsCME (must be one word). The app is free of charge and will 
be continuously updated during and after the course. 
To access the site using your cell phone or computer’s web browser: 
http://www.grupio.com/ScrippsCME
A N N U A L 30TH 
Treatments in Chronic Liver Disease 
New Treatments in Chronic Liver Disease MARCH 2 0 - 2 2 , 2 0 1 5 
pre-conference f e e s 
Included: Course tuition, access to conference materials (via mobile app and conference 
website) and internet in meeting space. 
Not Included: Printed course syllabus (presentations available via mobile app and conference 
website), meals, travel costs, parking and lodging. 
Thru Feb 24 - On-site 
Feb 23 Mar 16 after Mar 16 
$100 $125 $150 
main conference f e e s 
Included: Course tuition, access to conference materials (via mobile app and conference 
website) internet in meeting space, breakfast, breaks and lunch. 
Not Included: Printed course syllabus (presentations available via mobile app and conference 
website), travel costs, parking, lodging and dinner. 
Thru Feb 24 - On-site 
Feb 23 Mar 16 after Mar 16 
Physicians $305 $330 $355 
Non-Physician $235 $260 $285 
Fellows and Residents $165 $190 $215 
conference cour se ma terials 
Access to Conference App (included in cost of pre and main conferee fees) _____$100 
By completing this registration form and returning it to Scripps you are acknowledging 
compliance with all attendance policies. 
ways to register 
Online scripps.org/livercme 
Fax 858-652-5565 
Mail Scripps Conference Services & CME 
Clinical HemOnc 
11025 North Torrey Pines Rd. 
Suite 200, Maildrop: SCRC 200 
La Jolla, California 92037 
attendance policies 
Registration Confirmation 
A confirmation letter will be e-mailed to 
you upon receipt of the conference reg-istration 
form and payment. If you have 
not received it within two weeks, please 
contact the Scripps Conference Services & 
CME office. 
Attendee Cancellation, Substitution, 
Refund 
The course tuition is refundable, minus a 
$100 processing fee for the main confer-ence 
($40 for Fellows and Residents) and 
$20 processing fee for the pre-conference 
if your cancellation is received in writing 
no later than March 18, 2015. Attendee 
substitutions are allowed, but notification 
must be made in writing by March 18, 
2015. After this date, under no circum-stances 
will refunds, credits, or substitu-tions 
be granted. No refunds or credits will 
be given to “no shows.” 
Please Print Clearly. Should we have any conference communications or updates please provide your direct contact information. 
F I R S T N A M E , M I , L A S T N A M E D E G R E E ( M D , D O , P H D , R N , E T C ) 
B A D G E N A M E ( I F D I F F E R E N T F R O M A B O V E ) A F F I L I AT I O N / H O S P I TA L / C O M PA N Y S P E C I A L T Y 
D I R E C T M A I L I N G A D D R E S S 
C I T Y / S TAT E / Z I P C O D E 
D I R E C T T E L E P H O N E FA X 
E M A I L ASSISTANT E-MAIL 
ASSISTANT NAME ASSISTANT DIRECT TELEPHONE 
P L E A S E I N D I C AT E A N Y S P E C I A L N E E D S ( I N C L U D I N G D I E TA RY R E S T R I C T I O N S ) 
9Special requests will be considered and accommodated in full compliance with the Americans with Disabilities Act (ADA). 
Payment method Check, Please make checks payable to Scripps (in U.S. dollars only). 
If paying by credit card, please fill out the information below. Visa MasterCard Amex Discover 
C R E D I T C A R D N U M B E R E X P I R AT I O N D AT E S E C U R I T Y C O D E O N C A R D (required) 
N A M E O N C A R D S I G N AT U R E 
B I L L I N G A D D R E S S I F D I F F E R E N T F R O M A B O V E 
Estancia La Jolla, La Jolla, California 
Conference Fees & Registration
Scripps Conference Services & CME 
858-652-5400 
www.scripps.org/conferenceservices 
med.edu@scrippshealth.org 
A N N U A L 30TH 
New Treatments 
in Chronic 
Liver Disease 
MARCH 2 0 - 2 2 , 2 0 1 5 
MARCH 2 8 - 3 0 , 2 0 1 4 
Scripps Conference Services & CME 
11025 N. Torrey Pines Rd., Suite 200 
La Jolla, California 92037 
A N N U A L 30TH 
New Treatments 
in Chronic 
Liver Disease 
MARCH 2 0 - 2 2 , 2 0 1 5 
Pre-Conference: Fri., March 20, 2015 
Main Conference: March 21 - 22, 2015 
Estancia La Jolla, La Jolla, California 
Pre-Conference: Friday, March 20, 2015Main 
Conference: Saturday, March 21 - Sunday, March 22, 2015 
Estancia La Jolla, La Jolla, California 
2015 conference highlight s 
• Conference presentations will be available via mobile app 
and conference website. Internet will be available in the 
meeting space. 
• Half Day Pre-Conference Seminar reviewing the virology, 
genotypes and modes of infection of HCV. Participants 
will learn the details of new AASLD guidelines for 
treatment of HCV using DAA’s in combination with 
pegylated interferon and ribavirin. 
• Comprehensive presentations of the latest advances in 
hepatology with renowned faculty chosen for their 
expertise as well as teaching skills. 
• Endorsed by the American College of Gastroenterology. 
• Attendees will have opportunities to network with each 
other and interact with speakers to discuss topics from 
the course. 
target audience 
Hepatologists 
Gastroenterologists 
Infectious Disease 
Specialists 
Nurse Practitioners 
Physician Assistants 
Nurses 
Residents/Fellows 
and others desiring an up-date 
in these specialty areas 
Nonprofit Org. 
U.S. Postage 
PAID 
Permit No. 1981 
San Diego, CA

Mais conteúdo relacionado

Mais procurados

4th Annual Early Age Onset Colorectal Cancer Summit: Transforming Family Heal...
4th Annual Early Age Onset Colorectal Cancer Summit: Transforming Family Heal...4th Annual Early Age Onset Colorectal Cancer Summit: Transforming Family Heal...
4th Annual Early Age Onset Colorectal Cancer Summit: Transforming Family Heal...Colon Cancer Challenge Foundation
 
Epcm l9(new) screening for diseases
Epcm l9(new) screening for diseasesEpcm l9(new) screening for diseases
Epcm l9(new) screening for diseasesDr Ghaiath Hussein
 
Antimicrobial Stewardship and Applications to Common Infections
Antimicrobial Stewardship and Applications to Common InfectionsAntimicrobial Stewardship and Applications to Common Infections
Antimicrobial Stewardship and Applications to Common InfectionsPASaskatchewan
 
Challenges in managing adverse effects of immunotherapy treatment
Challenges in managing adverse effects of immunotherapy treatmentChallenges in managing adverse effects of immunotherapy treatment
Challenges in managing adverse effects of immunotherapy treatmentSCGH ED CME
 
Screening vs Diagnostic Tests & Concept of lead Time
Screening vs Diagnostic Tests & Concept of lead TimeScreening vs Diagnostic Tests & Concept of lead Time
Screening vs Diagnostic Tests & Concept of lead TimeDr. Abraham Mallela
 
Sepsis including Managing Low Risk
Sepsis including Managing Low RiskSepsis including Managing Low Risk
Sepsis including Managing Low RiskRecoveryPackage
 
GIT Kurdistan Board J club Functional heart burn16.
GIT Kurdistan Board J club Functional heart burn16.GIT Kurdistan Board J club Functional heart burn16.
GIT Kurdistan Board J club Functional heart burn16.Shaikhani.
 
SHARE Webinar: Why Should I Join a Clinical Trial with Dr. Hershman
SHARE Webinar: Why Should I Join a Clinical Trial with Dr. HershmanSHARE Webinar: Why Should I Join a Clinical Trial with Dr. Hershman
SHARE Webinar: Why Should I Join a Clinical Trial with Dr. Hershmanbkling
 
Eugm 2012 unknown - incivex drug development process overview road to findi...
Eugm 2012   unknown - incivex drug development process overview road to findi...Eugm 2012   unknown - incivex drug development process overview road to findi...
Eugm 2012 unknown - incivex drug development process overview road to findi...Cytel USA
 

Mais procurados (18)

592128
592128592128
592128
 
Easl recommendations
Easl recommendationsEasl recommendations
Easl recommendations
 
Hepatitis treatment viena
Hepatitis treatment vienaHepatitis treatment viena
Hepatitis treatment viena
 
4th Annual Early Age Onset Colorectal Cancer Summit: Transforming Family Heal...
4th Annual Early Age Onset Colorectal Cancer Summit: Transforming Family Heal...4th Annual Early Age Onset Colorectal Cancer Summit: Transforming Family Heal...
4th Annual Early Age Onset Colorectal Cancer Summit: Transforming Family Heal...
 
Epcm l9(new) screening for diseases
Epcm l9(new) screening for diseasesEpcm l9(new) screening for diseases
Epcm l9(new) screening for diseases
 
Antimicrobial Stewardship and Applications to Common Infections
Antimicrobial Stewardship and Applications to Common InfectionsAntimicrobial Stewardship and Applications to Common Infections
Antimicrobial Stewardship and Applications to Common Infections
 
2004 Cancer SOS paper
2004 Cancer SOS paper2004 Cancer SOS paper
2004 Cancer SOS paper
 
Challenges in managing adverse effects of immunotherapy treatment
Challenges in managing adverse effects of immunotherapy treatmentChallenges in managing adverse effects of immunotherapy treatment
Challenges in managing adverse effects of immunotherapy treatment
 
Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Inn...
Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Inn...Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Inn...
Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Inn...
 
Screening vs Diagnostic Tests & Concept of lead Time
Screening vs Diagnostic Tests & Concept of lead TimeScreening vs Diagnostic Tests & Concept of lead Time
Screening vs Diagnostic Tests & Concept of lead Time
 
Sepsis including Managing Low Risk
Sepsis including Managing Low RiskSepsis including Managing Low Risk
Sepsis including Managing Low Risk
 
Screening of disease
Screening of diseaseScreening of disease
Screening of disease
 
Screening
ScreeningScreening
Screening
 
CEIII IS PP
CEIII IS PPCEIII IS PP
CEIII IS PP
 
GIT Kurdistan Board J club Functional heart burn16.
GIT Kurdistan Board J club Functional heart burn16.GIT Kurdistan Board J club Functional heart burn16.
GIT Kurdistan Board J club Functional heart burn16.
 
SHARE Webinar: Why Should I Join a Clinical Trial with Dr. Hershman
SHARE Webinar: Why Should I Join a Clinical Trial with Dr. HershmanSHARE Webinar: Why Should I Join a Clinical Trial with Dr. Hershman
SHARE Webinar: Why Should I Join a Clinical Trial with Dr. Hershman
 
Eugm 2012 unknown - incivex drug development process overview road to findi...
Eugm 2012   unknown - incivex drug development process overview road to findi...Eugm 2012   unknown - incivex drug development process overview road to findi...
Eugm 2012 unknown - incivex drug development process overview road to findi...
 
New Services
New ServicesNew Services
New Services
 

Semelhante a Chronic Liver Disease Conference 2015

Rapid Integration Binder
Rapid Integration BinderRapid Integration Binder
Rapid Integration Binderflasco_org
 
Shaping the Future.Clinicians and Faculty Define - Strategies for the Next Er...
Shaping the Future.Clinicians and Faculty Define - Strategies for the Next Er...Shaping the Future.Clinicians and Faculty Define - Strategies for the Next Er...
Shaping the Future.Clinicians and Faculty Define - Strategies for the Next Er...hivlifeinfo
 
Aasld chronic hepatitisb2009
 Aasld chronic hepatitisb2009 Aasld chronic hepatitisb2009
Aasld chronic hepatitisb2009alejandro051071
 
bevacizumab chemotherapy treatment of metastastic colorectal cancer metasta...
 bevacizumab  chemotherapy treatment of metastastic colorectal cancer metasta... bevacizumab  chemotherapy treatment of metastastic colorectal cancer metasta...
bevacizumab chemotherapy treatment of metastastic colorectal cancer metasta...Мандухай Г.
 
Scripps 35th Annual Conference: Clinical Hematology & Oncology Brochure 2015
Scripps 35th Annual Conference: Clinical Hematology & Oncology Brochure 2015Scripps 35th Annual Conference: Clinical Hematology & Oncology Brochure 2015
Scripps 35th Annual Conference: Clinical Hematology & Oncology Brochure 2015Scripps Conference Services and CME
 
Benjamin Bearnot - New treatments for the infectious complications of substan...
Benjamin Bearnot - New treatments for the infectious complications of substan...Benjamin Bearnot - New treatments for the infectious complications of substan...
Benjamin Bearnot - New treatments for the infectious complications of substan...Benjamin Bearnot, MD
 
Hepatology - 2018 - Terrault - Update on prevention diagnosis and treatment...
Hepatology - 2018 - Terrault - Update on prevention  diagnosis  and treatment...Hepatology - 2018 - Terrault - Update on prevention  diagnosis  and treatment...
Hepatology - 2018 - Terrault - Update on prevention diagnosis and treatment...Sheik4
 
Cancer and the General Internist
Cancer and the General InternistCancer and the General Internist
Cancer and the General InternistLanceCatedral
 
MedicalResearch.com: Medical Research Exclusive Interviews February 10 2015
MedicalResearch.com:  Medical Research Exclusive Interviews February 10  2015MedicalResearch.com:  Medical Research Exclusive Interviews February 10  2015
MedicalResearch.com: Medical Research Exclusive Interviews February 10 2015Marie Benz MD FAAD
 
5th Annual Mid-Atlantic Peritoneal Malignancy
5th Annual Mid-Atlantic Peritoneal Malignancy5th Annual Mid-Atlantic Peritoneal Malignancy
5th Annual Mid-Atlantic Peritoneal MalignancyInova CME
 
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014hivlifeinfo
 
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014Hivlife Info
 
1st Gulf Hypertension Conference
1st Gulf Hypertension Conference1st Gulf Hypertension Conference
1st Gulf Hypertension ConferenceCheryl Prior
 
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...hivlifeinfo
 

Semelhante a Chronic Liver Disease Conference 2015 (20)

Rapid Integration Binder
Rapid Integration BinderRapid Integration Binder
Rapid Integration Binder
 
Shaping the Future.Clinicians and Faculty Define - Strategies for the Next Er...
Shaping the Future.Clinicians and Faculty Define - Strategies for the Next Er...Shaping the Future.Clinicians and Faculty Define - Strategies for the Next Er...
Shaping the Future.Clinicians and Faculty Define - Strategies for the Next Er...
 
Hepatitis C Drugs - Evidence to Demonstrate Effectiveness & Value
Hepatitis C Drugs - Evidence to Demonstrate Effectiveness & ValueHepatitis C Drugs - Evidence to Demonstrate Effectiveness & Value
Hepatitis C Drugs - Evidence to Demonstrate Effectiveness & Value
 
Aasld chronic hepatitisb2009
 Aasld chronic hepatitisb2009 Aasld chronic hepatitisb2009
Aasld chronic hepatitisb2009
 
bevacizumab chemotherapy treatment of metastastic colorectal cancer metasta...
 bevacizumab  chemotherapy treatment of metastastic colorectal cancer metasta... bevacizumab  chemotherapy treatment of metastastic colorectal cancer metasta...
bevacizumab chemotherapy treatment of metastastic colorectal cancer metasta...
 
Primary Care in Paradise Brochure 2015
Primary Care in Paradise Brochure 2015Primary Care in Paradise Brochure 2015
Primary Care in Paradise Brochure 2015
 
Impact diabetes
Impact diabetesImpact diabetes
Impact diabetes
 
Scripps 35th Annual Conference: Clinical Hematology & Oncology Brochure 2015
Scripps 35th Annual Conference: Clinical Hematology & Oncology Brochure 2015Scripps 35th Annual Conference: Clinical Hematology & Oncology Brochure 2015
Scripps 35th Annual Conference: Clinical Hematology & Oncology Brochure 2015
 
CV_1_2_15_linkedin
CV_1_2_15_linkedinCV_1_2_15_linkedin
CV_1_2_15_linkedin
 
Benjamin Bearnot - New treatments for the infectious complications of substan...
Benjamin Bearnot - New treatments for the infectious complications of substan...Benjamin Bearnot - New treatments for the infectious complications of substan...
Benjamin Bearnot - New treatments for the infectious complications of substan...
 
Precision Medicine in Oncology
Precision Medicine in OncologyPrecision Medicine in Oncology
Precision Medicine in Oncology
 
Hepatology - 2018 - Terrault - Update on prevention diagnosis and treatment...
Hepatology - 2018 - Terrault - Update on prevention  diagnosis  and treatment...Hepatology - 2018 - Terrault - Update on prevention  diagnosis  and treatment...
Hepatology - 2018 - Terrault - Update on prevention diagnosis and treatment...
 
Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer:...
Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer:...Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer:...
Empowering Changes and Revolutionizing Treatment and Equity in Breast Cancer:...
 
Cancer and the General Internist
Cancer and the General InternistCancer and the General Internist
Cancer and the General Internist
 
MedicalResearch.com: Medical Research Exclusive Interviews February 10 2015
MedicalResearch.com:  Medical Research Exclusive Interviews February 10  2015MedicalResearch.com:  Medical Research Exclusive Interviews February 10  2015
MedicalResearch.com: Medical Research Exclusive Interviews February 10 2015
 
5th Annual Mid-Atlantic Peritoneal Malignancy
5th Annual Mid-Atlantic Peritoneal Malignancy5th Annual Mid-Atlantic Peritoneal Malignancy
5th Annual Mid-Atlantic Peritoneal Malignancy
 
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
 
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014
 
1st Gulf Hypertension Conference
1st Gulf Hypertension Conference1st Gulf Hypertension Conference
1st Gulf Hypertension Conference
 
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...
 

Mais de Scripps Conference Services and CME (11)

Scripps Whittier Diabetes Program 2015
Scripps Whittier Diabetes Program 2015Scripps Whittier Diabetes Program 2015
Scripps Whittier Diabetes Program 2015
 
Structural Heart Intervention and Imaging Brochure 2015
Structural Heart Intervention and Imaging Brochure 2015Structural Heart Intervention and Imaging Brochure 2015
Structural Heart Intervention and Imaging Brochure 2015
 
Melanoma Conference 2015
Melanoma Conference 2015Melanoma Conference 2015
Melanoma Conference 2015
 
American College of Nutrition Conference 2015
American College of Nutrition Conference 2015American College of Nutrition Conference 2015
American College of Nutrition Conference 2015
 
Digital Medicine Brochure 2015
Digital Medicine Brochure 2015Digital Medicine Brochure 2015
Digital Medicine Brochure 2015
 
Future of Genomic Medicine Brochure 2015
Future of Genomic Medicine Brochure 2015 Future of Genomic Medicine Brochure 2015
Future of Genomic Medicine Brochure 2015
 
Brain Injury Conference Brochure 2015
Brain Injury Conference Brochure 2015Brain Injury Conference Brochure 2015
Brain Injury Conference Brochure 2015
 
Natural Supplements Brochure 2015
Natural Supplements Brochure 2015Natural Supplements Brochure 2015
Natural Supplements Brochure 2015
 
CIHA Syllabus
CIHA SyllabusCIHA Syllabus
CIHA Syllabus
 
Scripps 19th Annual Primary Care in Paradise 2014 Brochure
Scripps 19th Annual Primary Care in Paradise 2014 BrochureScripps 19th Annual Primary Care in Paradise 2014 Brochure
Scripps 19th Annual Primary Care in Paradise 2014 Brochure
 
Scripps Future of Genomic Medicine VII 2014
Scripps Future of Genomic Medicine VII 2014Scripps Future of Genomic Medicine VII 2014
Scripps Future of Genomic Medicine VII 2014
 

Último

Riddhi Kevadiya. WILLIAM SHAKESPEARE....
Riddhi Kevadiya. WILLIAM SHAKESPEARE....Riddhi Kevadiya. WILLIAM SHAKESPEARE....
Riddhi Kevadiya. WILLIAM SHAKESPEARE....Riddhi Kevadiya
 
Quality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICEQuality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICESayali Powar
 
3.26.24 Race, the Draft, and the Vietnam War.pptx
3.26.24 Race, the Draft, and the Vietnam War.pptx3.26.24 Race, the Draft, and the Vietnam War.pptx
3.26.24 Race, the Draft, and the Vietnam War.pptxmary850239
 
Vani Magazine - Quarterly Magazine of Seshadripuram Educational Trust
Vani Magazine - Quarterly Magazine of Seshadripuram Educational TrustVani Magazine - Quarterly Magazine of Seshadripuram Educational Trust
Vani Magazine - Quarterly Magazine of Seshadripuram Educational TrustSavipriya Raghavendra
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17Celine George
 
Department of Health Compounder Question ‍Solution 2022.pdf
Department of Health Compounder Question ‍Solution 2022.pdfDepartment of Health Compounder Question ‍Solution 2022.pdf
Department of Health Compounder Question ‍Solution 2022.pdfMohonDas
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfYu Kanazawa / Osaka University
 
How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17Celine George
 
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptxSandy Millin
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxraviapr7
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptxraviapr7
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.EnglishCEIPdeSigeiro
 
Protein Structure - threading Protein modelling pptx
Protein Structure - threading Protein modelling pptxProtein Structure - threading Protein modelling pptx
Protein Structure - threading Protein modelling pptxvidhisharma994099
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.raviapr7
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRATanmoy Mishra
 
SOLIDE WASTE in Cameroon,,,,,,,,,,,,,,,,,,,,,,,,,,,.pptx
SOLIDE WASTE in Cameroon,,,,,,,,,,,,,,,,,,,,,,,,,,,.pptxSOLIDE WASTE in Cameroon,,,,,,,,,,,,,,,,,,,,,,,,,,,.pptx
SOLIDE WASTE in Cameroon,,,,,,,,,,,,,,,,,,,,,,,,,,,.pptxSyedNadeemGillANi
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17Celine George
 
How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17Celine George
 
ARTICULAR DISC OF TEMPOROMANDIBULAR JOINT
ARTICULAR DISC OF TEMPOROMANDIBULAR JOINTARTICULAR DISC OF TEMPOROMANDIBULAR JOINT
ARTICULAR DISC OF TEMPOROMANDIBULAR JOINTDR. SNEHA NAIR
 

Último (20)

Riddhi Kevadiya. WILLIAM SHAKESPEARE....
Riddhi Kevadiya. WILLIAM SHAKESPEARE....Riddhi Kevadiya. WILLIAM SHAKESPEARE....
Riddhi Kevadiya. WILLIAM SHAKESPEARE....
 
Quality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICEQuality Assurance_GOOD LABORATORY PRACTICE
Quality Assurance_GOOD LABORATORY PRACTICE
 
3.26.24 Race, the Draft, and the Vietnam War.pptx
3.26.24 Race, the Draft, and the Vietnam War.pptx3.26.24 Race, the Draft, and the Vietnam War.pptx
3.26.24 Race, the Draft, and the Vietnam War.pptx
 
Vani Magazine - Quarterly Magazine of Seshadripuram Educational Trust
Vani Magazine - Quarterly Magazine of Seshadripuram Educational TrustVani Magazine - Quarterly Magazine of Seshadripuram Educational Trust
Vani Magazine - Quarterly Magazine of Seshadripuram Educational Trust
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17
 
Department of Health Compounder Question ‍Solution 2022.pdf
Department of Health Compounder Question ‍Solution 2022.pdfDepartment of Health Compounder Question ‍Solution 2022.pdf
Department of Health Compounder Question ‍Solution 2022.pdf
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
 
How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17
 
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptx
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.
 
Protein Structure - threading Protein modelling pptx
Protein Structure - threading Protein modelling pptxProtein Structure - threading Protein modelling pptx
Protein Structure - threading Protein modelling pptx
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
 
SOLIDE WASTE in Cameroon,,,,,,,,,,,,,,,,,,,,,,,,,,,.pptx
SOLIDE WASTE in Cameroon,,,,,,,,,,,,,,,,,,,,,,,,,,,.pptxSOLIDE WASTE in Cameroon,,,,,,,,,,,,,,,,,,,,,,,,,,,.pptx
SOLIDE WASTE in Cameroon,,,,,,,,,,,,,,,,,,,,,,,,,,,.pptx
 
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdfPersonal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17
 
How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17
 
ARTICULAR DISC OF TEMPOROMANDIBULAR JOINT
ARTICULAR DISC OF TEMPOROMANDIBULAR JOINTARTICULAR DISC OF TEMPOROMANDIBULAR JOINT
ARTICULAR DISC OF TEMPOROMANDIBULAR JOINT
 

Chronic Liver Disease Conference 2015

  • 1. Endorsed By A N N U A L 30TH New Treatments in Chronic Liver Disease FRIDAY, MARCH 20 – SUNDAY, MARCH 22, 2015 MARCH 3 1 - A P R I L 1 , 2 0 1 2 Pre-Conference: Friday, March 20, 2015 Main Conference: Saturday, March 21 – Sunday, March 22, 2015 Estancia La Jolla • La Jolla, California
  • 2. Course Introduction Faculty course o verv i ew This CME conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials using new drugs to treat chronic viral hepatitis B and C, non-alcoholic course d i r e ctor Paul Pockros, MD, FACG Director, Liver Disease Center Scripps Clinic Director of Clinical Research Scripps Translational Science Institute La Jolla, California scripps f aculty Catherine Frenette, MD Medical Director of Liver Transplantation Director of Center of Excellence for HCC Scripps Center for Cell and Organ Transplantation Scripps Clinic La Jolla, California Jill Lane, MD Division of Gastroenterology/Hepatology Scripps Clinic La Jolla, California guest f aculty Ira Jacobson, MD, FACG Chief Division of Gastroenterology and Hepatology Vincent Astor Distinguished Professor of Medicine The Joan Sanford I. Weill Medical College of Cornell University Attending Physician New York – Presbyterian Hospital, Cornell Campus New York, New York Keith Lindor, MD, FACG Executive Vice Provost and Dean College of Health Solutions Arizona State University Phoenix, Arizona Rohit Loomba, MD, MHSc Associate Professor of Clinical Medicine Director, NAFLD Translational Research Unit UCSD School of Medicine La Jolla, CA Lisa Richards, FNP-BC Certified Family Nurse Practitioner University of California San Diego Medical Center San Diego, California Bruce Allen Runyon, MD Clinical Professor of Medicine Director of Hepatology UCLA Medical Center Santa Monica, California Norman Sussman, MD Associate Professor, Liver Center Baylor College of Medicine Houston, Texas Tram T. Tran, MD, FACG Medical Director Liver Transplant and Hepatology Associate Professor of Medicine Cedars Sinai Medical Center Los Angles, California Faculty Disclosure In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the edu-cational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Employees of a commercial interest with business lines or products relating to the content of the CME activity will not participate in the planning or any accredited portion of the conference. Disclosure will be made to all participants at the conference location, prior to the educational activity commencement. fatty liver diseases, primary biliary cirrhosis, primary sclerosing chol-angitis, hepatocellular carcinoma and complications of end-stage liver disease will be reviewed in detail. New Treatments in Chronic Liver Disease is a com-prehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases. There was a fundamental change in the treatment of chronic hepatitis C in late 2014 with the addition of multiple new direct-acting antiviral (DAAs) drugs to current standard of care for all genotypes. There will be two separate lectures devoted to this topic this year. The first will be on currently available all-oral therapies that were approved in late 2014. The second will be on fu-ture therapies that will shorten duration and lower cost of a cure. As well, the pre-conference will extensively detail currently available treatment regimens with the goal of introducing the topic to new treaters. We anticipate that there will be a number of new demands placed on treat-ment providers, including screening, access to treatment, costs of therapy and the continuation of complex algorithms for interferon-based regimens. Look-ing beyond 2015, we see numerous combinations of DAA’s in development including protease inhibitors, nucleoside polymerase inhibitors, non-nucleo-side polymerase inhibitors and N55A inhibitors. Most of these agents are in phase 3 development and a number have completed studies and are awaiting FDA review. In hepatitis B, the treatments have not changed but there is more mature data available on long-term HBsAg loss and clinical outcomes. The ad-dition of immune-mediated therapies for HBV with the goal of curing the dis-ease has been included in this year’s program. New therapies for NAFLD and NASH are in development and important new data showing positive results in NASH will be presented at this meeting. The explosive growth of NASH in the US has created a significant need for effective drug therapy. The diagnosis and treatment of hepatocellular carcinoma will be updated as this disease is one of the few cancers with a growing incidence in the US. New oral therapy is moving this field forward. There will be an update on management of hepatic encephalopathy, hyponatremia and the management of complications in the transplant candidate. educ ational o b j e c t i ves After participating in this course, attendees should be able to: • Understand the details of the AASLD guidelines for treatment of HCV using DAA’s in IFN-free regimens. • Review our current knowledge of NAFLD and non-alcoholic steato-hepatitis and explore the use of new agents and approaches to treatment of the conditions. • Integrate the algorithm for a therapeutic approach to treatment of HBV using anti-virals. • Discuss therapies for HCV including NS5A, protease and polymerase inhibitors. • Update the skills and management required for transplant hepatology. • Apply current options of therapy for hepatocellular carcinoma to determine the best approach for your patients. • Discuss future treatment paradigms for HCV direct-acting antiviral drug. • Describe the diagnosis and treatment of PBC and PSC. • Integrate treatment options discussed for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH or inherited genetic disorder. • Discuss the issues complicating drug treatment in decompensated cirrhosis, hepatic encephalopathy and hyponatremia. • Review the management of complications beta-blocker therapy in ESLD.
  • 3. Program pre-conference o verv i ew We will review the virology, genotypes, modes of infection of HCV and characteristics of the clinical illness caused by acute and chronic infections. Tests for HCV, including PCR assays and genotyping, interpretations and indications for liver biop-sies and complications of cirrhosis will all be discussed. We will show how to initiate and monitor patients during treat-ment with simeprevir and sofosbuvir, manage side effects of therapy and deal with various patient populations including African Americans, HIV-coinfected and ESLD patients. Lastly, new drugs in development including protease inhibitors, other nucleoside and non-nucleoside polymerase inhibitors, NS5A inhibitors, and other novel agents will be discussed. pre-conference Friday, March 20, 2015 12:30 p.m. Registration 1 p.m. Welcome & Introduction Paul Pockros, MD, FACG 1:10 p.m. Update on HCV Diagnostics Paul Pockros, MD, FACG 1:40 p.m. Update on Current therapy with IFN-free all-oral regimens Paul Pockros, MD, FACG main conference Saturday, March 21, 2015 7:30 a.m. Registration, Breakfast & View Exhibits 8 a.m. Welcome & Introduction 30 years of the Scripps Liver Conference Paul Pockros, MD, FACG MODERATOR Paul Pockros, MD, FACG 8:15 a.m. Beta-Blockers and ESLD Mortality Bruce Runyon, MD 9 a.m. New Treatments in Development for NASH Rohit Loomba, MD, MHSc 9:45 a.m. Break & View Exhibits 10:15 a.m. Chronic Hepatitis B: Directions Towards A Cure? Tram Tran, MD 11 a.m. Debate NASH: Treat Everyone with OCA When It’s Approved Rohit Loomba, MD, MHSc NASH: Wait For More Evidence Before Treating with OCA Bruce Runyon, MD 11:15 a.m. Panel Discussion: Morning Speakers 11:45 a.m. Lunch MODERATOR Catherine Frenette, MD W.S. Haubrich Honorary Lecturer 1 p.m. All-Oral Therapies for HCV Ira Jacobson, MD, FACG 1:45 p.m. HCV: What’s Left for Future Treatments? Paul Pockros, MD, FACG 2:30 p.m. Break & View Exhibits 3 p.m. Debate #1: Treat HBeAg-negative HBV Forever Tram Tran, MD Stop Therapy in HBeAg-negative HBV Patients after Two Years Paul Pockros, MD, FACG 2:40 p.m. Break & View Exhibits 3 p.m. Pre and Post Liver Transplant Catherine Frenette, MD 3:30 p.m. Case Presentation, Discussion and Q&A • Side-Effects Management • Selection of Treatment • Cirrhosis: Who to Treat • Special Populations Lisa Richards, FNP-BC 5 p.m. Adjourn Saturday (continued) 3:15 p.m. Debate #2: HCV: Treat For Cure at Any Cost Ira Jacobson, MD, FACG HCV: Treat For Cost-Effective Cure and Salvage Those Who Fail Paul Pockros, MD, FACG 3:30 p.m. Panel Discussion: Afternoon Speakers 4:30 p.m. Adjourn Sunday, March 22, 2015 7:30 a.m. Breakfast & View Exhibits MODERATOR Jill Lane, MD 8 a.m. Emerging Therapies for PBC and PSC Keith Lindor,MD, FACG 8:45 a.m. NAFLD: What To Do For The IBS of The Hepatologist? Norman Sussman, MD 9:30 a.m. How to Have a Successful Outcome with HCC Catherine Frenette, MD 10:15 a.m. Break & View Exhibits 10:45 a.m. Debate Transplant Outcomes Depend on What Region You’re In Norman Sussman, MD Transplant Outcomes Depend on Your ICU Care Catherine Frenette, MD 11 a.m. Panel Discussion 11:45 a.m. Adjournment
  • 4. accreditation Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to pro-vide continuing medical education for physicians. Scripps Health designates this live activ-ity for a maximum of 13.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Credit Breakdown: Pre-Conference (Fri): 3.5 Main Conference (Sat-Sun): 10 Nurses: For the purpose of recertifica-tion, the American Nurses Credential-ing Center accepts AMA PRA Category 1 Credits™ issued by organizations accredited by the ACCME. For the purpose of re-licensure, the California Board of Registered Nursing accepts AMA PRA Category 1 Credits™. Most states’ Board of Registered Nursing ac-cept AMA PRA Category 1 Credit(s)™ as meeting continuing education re-quirements for license renewal. Nurses should check with their state board re-garding use of CME credit. Nurse Practitioners: This program will be submitted to the American Associa-tion of Nurse Practitioners for continu-ing education credit. Physicians Assistants: The American Academy of Physician Assistants accepts Category 1 credit from AMA Category 1 CME organizations accredited by ACCME. educational gr ants This course is supported, in part, by educational grants from industry, in accordance with ACCME accreditation Standards for Commercial Support. At the time of printing, a complete list-ing of commercial supporters was not available. Appropriate acknowledge-ment will be given to all supporters at the time of the educational activity. About William S. Haubrich, MD Dr. Haubrich graduated from Franklin & Marshall College in Lacaster, Penn-sylvania in 1943 and from the medical school of Case-Western Reserve University in Cleveland, Ohio in 1947. His postgraduate training in pathology and internal medicine was at Cleveland City Hospital (now MetroHealth). His mentor in gastroenterology was Dr. Henry L. Bockus at the Graduate Hospital of the University of Pennsylvania in Philadelphia. During the Korean War he served as gastroenterologist to the Madigan Army Hospital at Fort Lewis, Washington. From 1955 to 1970 he was on the gastroenter-ology staff at the Henry Ford Hospital in Detroit. In 1970 he was appoint-ed Clinical Member at the Scripps Clinic and Research Foundation where he headed the division of gastroenterology from 1972 to 1984. He served as Clinical Professor of Medicine at the University of California, San Diego since 1971. His scholarly contributions include more than 200 journal articles and textbook chapters. He was consultant in life sciences to the editors of the 3rd and 4th editions of the American Heritage Dictionary of the English Language. In 1960 he was awarded the Vincent Lyon Prize by the American Gastroen-terology Association and in 1985 received the Rudolf Schindler Award of the American Society of Gastrointestinal Endoscopy. He was named a Master of the American College of Physicians. Dr. Haubrich passed away peacefully at his home in La Jolla in October 2012. Conference Location Estancia La Jolla Hotel 9700 N. Torrey Pines Road, La Jolla, California 92037 855-318-7602 estancialajolla.com Please make your own sleeping room reservation, no later than March 3, 2015. Mention you are with the Scripps Liver Disease Conference to receive the reduced rate of $199 per night, plus the $12 hospitality service fee (dis-counted from $17), which includes: Welcome beverage at check-in, guest room bottled water daily, wireless internet access in guest room and common area, daily newspaper, in room coffee & morning coffee service in Trinitas Cellars Wine Bar, local & 800 call access and access to Fitness Center, Internet Office and Pool area. Download the Scripps CME App All conference information including a detailed agenda, faculty listing, faculty disclosures, industry support, attendee list, and course materials can be found on the free Scripps CME conference app for iPhone, iPad, Android, and BlackBerry. To download the app on your smart phone or other device visit the appropriate app store and search ScrippsCME (must be one word). The app is free of charge and will be continuously updated during and after the course. To access the site using your cell phone or computer’s web browser: http://www.grupio.com/ScrippsCME
  • 5. A N N U A L 30TH Treatments in Chronic Liver Disease New Treatments in Chronic Liver Disease MARCH 2 0 - 2 2 , 2 0 1 5 pre-conference f e e s Included: Course tuition, access to conference materials (via mobile app and conference website) and internet in meeting space. Not Included: Printed course syllabus (presentations available via mobile app and conference website), meals, travel costs, parking and lodging. Thru Feb 24 - On-site Feb 23 Mar 16 after Mar 16 $100 $125 $150 main conference f e e s Included: Course tuition, access to conference materials (via mobile app and conference website) internet in meeting space, breakfast, breaks and lunch. Not Included: Printed course syllabus (presentations available via mobile app and conference website), travel costs, parking, lodging and dinner. Thru Feb 24 - On-site Feb 23 Mar 16 after Mar 16 Physicians $305 $330 $355 Non-Physician $235 $260 $285 Fellows and Residents $165 $190 $215 conference cour se ma terials Access to Conference App (included in cost of pre and main conferee fees) _____$100 By completing this registration form and returning it to Scripps you are acknowledging compliance with all attendance policies. ways to register Online scripps.org/livercme Fax 858-652-5565 Mail Scripps Conference Services & CME Clinical HemOnc 11025 North Torrey Pines Rd. Suite 200, Maildrop: SCRC 200 La Jolla, California 92037 attendance policies Registration Confirmation A confirmation letter will be e-mailed to you upon receipt of the conference reg-istration form and payment. If you have not received it within two weeks, please contact the Scripps Conference Services & CME office. Attendee Cancellation, Substitution, Refund The course tuition is refundable, minus a $100 processing fee for the main confer-ence ($40 for Fellows and Residents) and $20 processing fee for the pre-conference if your cancellation is received in writing no later than March 18, 2015. Attendee substitutions are allowed, but notification must be made in writing by March 18, 2015. After this date, under no circum-stances will refunds, credits, or substitu-tions be granted. No refunds or credits will be given to “no shows.” Please Print Clearly. Should we have any conference communications or updates please provide your direct contact information. F I R S T N A M E , M I , L A S T N A M E D E G R E E ( M D , D O , P H D , R N , E T C ) B A D G E N A M E ( I F D I F F E R E N T F R O M A B O V E ) A F F I L I AT I O N / H O S P I TA L / C O M PA N Y S P E C I A L T Y D I R E C T M A I L I N G A D D R E S S C I T Y / S TAT E / Z I P C O D E D I R E C T T E L E P H O N E FA X E M A I L ASSISTANT E-MAIL ASSISTANT NAME ASSISTANT DIRECT TELEPHONE P L E A S E I N D I C AT E A N Y S P E C I A L N E E D S ( I N C L U D I N G D I E TA RY R E S T R I C T I O N S ) 9Special requests will be considered and accommodated in full compliance with the Americans with Disabilities Act (ADA). Payment method Check, Please make checks payable to Scripps (in U.S. dollars only). If paying by credit card, please fill out the information below. Visa MasterCard Amex Discover C R E D I T C A R D N U M B E R E X P I R AT I O N D AT E S E C U R I T Y C O D E O N C A R D (required) N A M E O N C A R D S I G N AT U R E B I L L I N G A D D R E S S I F D I F F E R E N T F R O M A B O V E Estancia La Jolla, La Jolla, California Conference Fees & Registration
  • 6. Scripps Conference Services & CME 858-652-5400 www.scripps.org/conferenceservices med.edu@scrippshealth.org A N N U A L 30TH New Treatments in Chronic Liver Disease MARCH 2 0 - 2 2 , 2 0 1 5 MARCH 2 8 - 3 0 , 2 0 1 4 Scripps Conference Services & CME 11025 N. Torrey Pines Rd., Suite 200 La Jolla, California 92037 A N N U A L 30TH New Treatments in Chronic Liver Disease MARCH 2 0 - 2 2 , 2 0 1 5 Pre-Conference: Fri., March 20, 2015 Main Conference: March 21 - 22, 2015 Estancia La Jolla, La Jolla, California Pre-Conference: Friday, March 20, 2015Main Conference: Saturday, March 21 - Sunday, March 22, 2015 Estancia La Jolla, La Jolla, California 2015 conference highlight s • Conference presentations will be available via mobile app and conference website. Internet will be available in the meeting space. • Half Day Pre-Conference Seminar reviewing the virology, genotypes and modes of infection of HCV. Participants will learn the details of new AASLD guidelines for treatment of HCV using DAA’s in combination with pegylated interferon and ribavirin. • Comprehensive presentations of the latest advances in hepatology with renowned faculty chosen for their expertise as well as teaching skills. • Endorsed by the American College of Gastroenterology. • Attendees will have opportunities to network with each other and interact with speakers to discuss topics from the course. target audience Hepatologists Gastroenterologists Infectious Disease Specialists Nurse Practitioners Physician Assistants Nurses Residents/Fellows and others desiring an up-date in these specialty areas Nonprofit Org. U.S. Postage PAID Permit No. 1981 San Diego, CA